Table 3. Outcomes for patients enrolled... | American Society of Hematology

Table 3.

Outcomes for patients enrolled in the Midotarg substudy receiving DAGO+m

	DAGO1+m n = 39	DAGO2+m n = 38
Response, %
ORR (CR + CRi)	90	92
CR	77	81.5
CRi	13	10.5
CR/CR_i after course 1	85	89
Postcourse 2 PB MRD negative for NPM1	18/24 (75%)	19/22 (86%)
Allogeneic transplant in CR1	11	7
Survival, %
2-Year OS	76	78
2-Year EFS	59	66
2-Year cumulative incidence of relapse	33	29
2-Year relapse-free survival	66	71

	DAGO1+m n = 39	DAGO2+m n = 38
Response, %
ORR (CR + CRi)	90	92
CR	77	81.5
CRi	13	10.5
CR/CR_i after course 1	85	89
Postcourse 2 PB MRD negative for NPM1	18/24 (75%)	19/22 (86%)
Allogeneic transplant in CR1	11	7
Survival, %
2-Year OS	76	78
2-Year EFS	59	66
2-Year cumulative incidence of relapse	33	29
2-Year relapse-free survival	66	71

ORR, overall response rate.